Actelion abstract details 'promising' macitentan data

A published abstract ahead of a science meeting next week gave Actelion's ($ATLN) investors a look at its late-stage data for macitentan, a key new therapy for pulmonary arterial hypertension it will depend on to replace its primary product on the market. A 10 mg dose reduced the risk of death by 38% when compared to a rival drug and more than half compared to a placebo, according to a report from Bloomberg. And analysts were encouraged. Jefferies' Peter Welford called the data "impressive. Given that PAH hospitalization is a hard endpoint, and one I think payers will respond to, to reduce that by 50% with the 10-milligram dose I would say is very promising." The drug will be needed to replace Tracleer once it loses patent protection. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.